Abstract
Purpose
TP53/EGFR co-mutation has been reported to affect the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in lung adenocarcinoma (LUAD). However, its impact on survival is unclear. In this analysis, we explored the prognostic effect of TP53/EGFR co-mutation in LUAD.
Methods
Clinical data and transcriptome sequencing of LUAD patients with matched genomic data were downloaded from the Cancer Genome Atlas (TCGA) database for overall survival (OS) analysis. Differential expression genes (DEGs) were recognized by R software and bioconductor package. Clusterprofiler was used for functional analysis. STRING was used for estimating PPI information and plug-in CytoHubba to screen hub modules in Cytoscape. The association between tumor mutation burden (TMB) and survival was also analyzed.
Results
OS was shorter for patients carrying TP53 mutation (MUT) than that of wild type (WT) (37.7 m vs 52.8 m; p = 0.040, HR = 1.38, 95% CI 1.01–1.89). Dual TP53/EGFR-MUT was associated with inferior OS compared with the dual WT/WT cohort (38.4 m vs 51.9 m; p = 0.023, HR 1.83, 95% CI 0.95–3.52). 316 DEGs between dual TP53/EGFR-MUT and dual WT/WT samples were obtained and functional analysis made known that DEGs were strikingly enriched in regulating the metabolism of important amino acids, cell division, cell cycle regulation, cell adhesion, and extracellular matrix composition. KEGG analysis discovered that DEGs were mainly enriched in signaling pathways such as PI3K-Akt, cytokine–cytokine receptor interaction, focal adhesions, and extracellular matrix receptor interaction. PPI network suggested that GPC3, CCL28, GPR37, and NPY genes were up-regulated in dual mutation samples. OS in the high TMB cohort was significantly better than that in the low TMB in patients with TP53 MUT(43.2 m vs 32.4 m; P = 0.007, HR = 0.52, 95% CI: 0.34-0.81), as well as in the combination of TP53 MUT and EGFR WT group (44.4 m vs 31.2 m; P = 0.021, HR = 0.55, 95% CI 0.34 − 0.89).
Conclusions
TP53 MUT is a poor prognostic factor in LUAD patients, and the prognosis of TP53/EGFR co-mutation is worse. GPC3, CCL28, GPR37, and NPY may be novel prognostic markers and potential therapeutic targets for patients with dual TP53/EGFR mutation LUAD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baris U, Aynura M, Özgür Ö, Duygu U-Ç, Tülin Y, Fatima A-K (2020) Neuropeptide Y is involved in the regulation of quiescence of hematopoietic stem cells. Neuropeptides. https://doi.org/10.1016/j.npep.2020.102029
Biton J, Mansuet-Lupo A, Pecuchet N, Alifano M, Ouakrim H, Arrondeau J et al (2018) TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. Clin Cancer Res 24(22):5710–5723. https://doi.org/10.1158/1078-0432.CCR-18-0163
Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M et al (2017) Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res 23(9):2195–2202. https://doi.org/10.1158/1078-0432.CCR-16-0966
Deng LL, Gao G, Deng HB, Wang F, Wang ZH, Yang Y (2019) Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC. J Cancer Res Clin Oncol 145(10):2613–2624. https://doi.org/10.1007/s00432-019-03001-2
Frezza C (2016) Cancer metabolism: addicted to serine. Nat Chem Biol 12(6):389–390. https://doi.org/10.1038/nchembio.2086
Gerlza T, Trojacher C, Jeremic D, Krieger E, Adage T, Kungl A (2020) PEGylation of a glycosaminoglycan-binding, dominant-negative CXCL8 mutant retains bioactivity in vitro and in vivo. Cytokine 127:154942. https://doi.org/10.1016/j.cyto.2019.154942
Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J et al (2016) Focal adhesion kinase inhibitors in combination with erlotinib demonstrate enhanced anti-tumor activity in non-small cell lung cancer. PLoS ONE 11(3):e0150567. https://doi.org/10.1371/journal.pone.0150567
Kang SP, Gergich K, Lubiniecki GM, de Alwis DP, Chen C, Tice MAB et al (2017) Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. Ann Oncol 28(6):1388–1398. https://doi.org/10.1093/annonc/mdx076
Killock D (2017) Lung Cancer: frontline nivolumab - CheckMate 026 ends in stalemate. Nat Rev Clin Oncol 14(8):458–459. https://doi.org/10.1038/nrclinonc.2017.102
Labbe C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C et al (2017) Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer 111:23–29. https://doi.org/10.1016/j.lungcan.2017.06.014
Li F, Du X, Zhang H, Ju T, Chen C, Qu Q et al (2017) Next-generation sequencing of Chinese stage IV lung cancer patients reveals an association between EGFR mutation status and survival outcome. Clin Genet 91(3):488–493. https://doi.org/10.1111/cge.12809
Mohan T, Deng L, Wang BZ (2017) CCL28 chemokine: an anchoring point bridging innate and adaptive immunity. Int Immunopharmacol 51:165–170. https://doi.org/10.1016/j.intimp.2017.08.012
Pacold ME, Brimacombe KR, Chan SH, Rohde JM, Lewis CA, Swier LJ et al (2016a) A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nat Chem Biol 12(6):452–458. https://doi.org/10.1038/nchembio.2070
Pacold ME, Brimacombe KR, Chan SH, Rohde JM, Lewis CA, Swier LJ et al (2016b) Corrigendum: a PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nat Chem Biol 12(8):656. https://doi.org/10.1038/nchembio0816-656
Ramalingam S, Hui R, Gandhi L, Carcereny E, Felip E, Ahn M-J et al (2016) P239: long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab. J Thoracic Oncol. https://doi.org/10.1016/j.jtho.2016.08.110
Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D et al (2018) Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol 36(7):633–641. https://doi.org/10.1200/JCO.2017.75.3384
Tsuchiya N, Yoshikawa T, Fujinami N, Saito K, Mizuno S, Sawada Y et al (2017) Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology 6(10):e1346764. https://doi.org/10.1080/2162402X.2017.1346764
VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J et al (2017) Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes. Lung Cancer 106:17–21. https://doi.org/10.1016/j.lungcan.2017.01.011
Wright R, Sherwood P, Stafford W, Correia JJ (2016) Analytical ultracentrifuge studies of a cytokine, soluble receptor interaction: comparison of simulations and experiments. Biophys J. https://doi.org/10.1016/j.bpj.2015.11.2078
Xavier M, Rodrigo AC, Francisco C (2019) G protein-coupled receptor 37 (GPR37) emerges as an important modulator of adenosinergic transmission in the striatum. Neural Regener Res. https://doi.org/10.4103/1673-5374.259610
Yang J, Qin G, Luo M et al (2015) Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT. Cell Death Dis 6:e1829. https://doi.org/10.1038/cddis.2015.197
Yu S, Toshiaki Y, Kazuya O, Mayuko Y, Nobuhiro T, Mari T et al (2016) Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. https://doi.org/10.1080/2162402x.2015.1129483
Yudong W, Zhijie W, Sarina PP, Filip J, Vivek S, Naiyi S et al (2018) Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget. https://doi.org/10.18632/oncotarget.25947
Zhao H, Sun J, Shao J, Wu G et al (2019) Glucose transporter 1 promotes the malignant phenotype of non-small cell lung cancer through integrin β1/Src/FAK signaling. J Cancer. https://doi.org/10.7150/jca.30772
Acknowledgements
This study was funded by a research Grant from the Postdoctoral Scientific Research Developmental Fund (Grant No. LBH-Q16143) provided by the Administration Office of Heilongjiang Postdoctoral Program, China, and a Special fund for clinical research from Wu Jieping medical foundation (Grant No. 320.6750.18050). Our thanks to all participants who consented to take part in this trial.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declared that they have no conflict of interest.
Ethical approval
TCGA dataset is used in the study.
Informed consent
Because it is a public database, no informed consent is required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wang, F., Zhao, N., Gao, G. et al. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma. J Cancer Res Clin Oncol 146, 2851–2859 (2020). https://doi.org/10.1007/s00432-020-03340-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-020-03340-5